Joint Formulary & PAD

Triamcinolone acetonide - Macular oedema

You are here : Home > Formulary Search > Triamcinolone acetonide - Macular oedema

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Intravitreal injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :
Important

40mg/ml preservative free ophthalmic suspension (Intracinol brand). Unlicensed.

 

Status 2

Red
Formulations :
  • Subtenon / Optical floor injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Off Label
Restrictions / Comments :
Important

RSCH: use Intracinol for subtenon / orbital floor injections. Off-label use.

(Noting that Kenalog has been discontinued Jun 2025)

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Triamcinolone acetonide
Indication :
Macular oedema
Group Name :
Keywords :
Brand Names Include :
Intracinol, Kenalog
Important Information :

 

 

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
2

Committee Recommendations (1)

02 Oct 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.

Other Indications

Below are listed other indications that Triamcinolone acetonide is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Macular oedema.

  • No records returned.